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histochemistry or by genetic sequencing). Compared with Pompe 
disease, cognitive impairment and retinitis pigmentosa may be 
distinctive features of the diseases. 
Adult Onset
Adult-onset acid maltase deficiency may simulate limb-gir-
dle dystrophy and the heart may represent a rare finding. Nev-
ertheless, the cardiac phenotype of adults with GDSII is poorly 
characterized, so far. 
Descriptions of heart abnormalities in adults with Pompe 
disease are sparse. Recently, a relatively large cohort of adults 
(87 patients, median age 44 years old, 51% males) with Pompe 
disease have been evaluated (7). A short PR interval was present 
in 10%, 7% showed a decreased left ventricular systolic func-
tion, and 5% had elevated left ventricular mass on echocardio-
gram. No change in cardiovascular status associated with en-
zyme replacement therapy (ERT) was observed. 
Severe vacuolization of vascular smooth muscle with ac-
cumulation of glycogen, particularly involving large and small 
cerebral  arteries  with  aneurysm  formation,  have  previously 
been reported (8, 9). Gungor D et al. (10) described survival 
of 268 patients with Pompe diseases, collected in a prospec-
tive international observational study conducted between 2002 
and 2009. Out of 34 deaths reported, the cause of death was 
recognized in 9 patients, including 1 patient who died for aortic 
dissection. The evidence of smooth muscle involvement seem 
to be confirmed by the finding of an increased aortic stiffness in 
adults with Pompe disease (11), which may be due to glycogen 
storage in the vessel wall, causing reduced vascular elasticity. 
These findings deserve future investigations. 
SUMMARY CLINICAL SYNOPSIS
Principal investigations:
•   ECG: short PR (WPW syndrome), signs of left ven-
tricular hypertrophy with repolarization abnormalities, 
Atrioventricular and/or intraventricular conduction de-
lays.
•   Echo:  left  ventricular  hypertrophy  (or,  biventricular 
hypertrophy), with or without: a) left ventricular out-
flow tract obstruction (about 30%); b) systolic dysfunc-
tion; c) diastolic dysfunction (generally, present).
Other investigations:
•   24 hours ECG Holter: intermittent WPW and/or con-
duction delays.
•   Functional capacity study: by six minute walking test 
and/or cardiopulmonary exercise test.
•   Cardiac  Magnetic  Resonance  Imaging  (CMRI),  with 
late gadolinueum analysis: to study cardiac morphology 
and function, and to determinate a non invasive, “texture 
characterization” of the cardiac muscle.
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Pompe disease is a single disease continuum that includes 
variable neuromuscular symptoms and rates of progression. 
However, specific clinical features, such as an early onset of 
respiratory problems preceding limb muscular weakness, dis-
tinguish Pompe disease from other neuromuscular diseases in 
which respiratory insufficiency occurs after loss of ambula-
tion. 
The  management  of  Pompe  disease  also  differs  from 
other neuromuscular diseases in that specific treatment is now 
available, making early recognition of the disease a priority. 
Late-onset form of Pompe disease, that may occur at any age 
after the first year of life, is characterized by slow and progres-
sive loss of function of skeletal muscles. Respiratory failure 
is the major cause of morbidity and mortality. The evaluation 
and monitoring of parameters such as FVC, MIP, MEP, blood 
gases, together with the clinical examination can delineate the 
profile and the decline in lung function, in order to provide 
early and effective therapeutic intervention. In patients with 
restrictive chest wall disease, the indication in VMD should be 
in the presence of symptoms such as fatigue, dyspnea, morn-
ing headaches, disturbed sleep, daytime hypersomnia associ-204
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SESSION 2. MANAGEMENT OF POMPE DISEASE
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Since 2006 ERT is available in Europe and numerous stud-
ies were reported both in infantile and in juvenile - adult patients 
that demonstrated variable efficacy (1, 2). We have followed in-
fants treated with ERT either early in the first year or later. In 
one child with onset at birth, diagnosed in the third day of life 
we observed an excellent long-term clinical response on severe 
bradycardia and reduction of left ventricular mass index in car-
diomyopathy (3) while in another child where the therapy was 
post-pond no such response was observed: in this second case 
a large connective tissue replacement was present in the biopsy 
after ERT. In juvenile and late onset cases a large experience 
was collected by the Italian group of GSDII (4) and will be soon 
reported in full. Beside the clinical follow-up we also did a re-
peated second biopsy after ERT in two cases after 6 months in 
a 17 year old juvenile case and after 36 months of ERT in a 63 
year ventilator dependent woman and we observed less degree 
of vacuolization in muscle fibers. We documented that ERT im-
proves muscle fiber trophism and decreases PAS positivity, as 
well as the extensive muscle autophagic vacuolization. We did 
observe that ERT is effective in both infantile and late-onset GS-
DII cases, but at a different extent. To explain the difference of 
ERT in late onset cases we suppose that fiber sarcolemmal mem-
brane  compartimentalization  around  autophagosomes  might 
contribute to the different response in infants and adults; in fact 
we previously reported (5) that there is a greater degree of fiber 
sarcolemmal membranes around vacuoles in muscle fibers of 
late-onset GSDII, versus classical infantile Pompe patients. This 
protective mechanism may influence the delivery of ERT in adult 
cases. Furthermore a high antibody titer against recombinant en-
zyme has been observed (1, 6) both in infants and in adults and 
might influence ERT efficacy. Finally body composition (I.e fat 
and connective tissue) and the different mannose receptor den-
sity in various tissues (heart, skeletal muscle, diaphragm) has to 
be considered. ERT is the first treatment developed for GSDII, 
but it needs further refinements. Several trials are in fact explor-
ing new avenues of treatment (chaperons, new compounds with 
different affinity for mannose receptor, immunotherapy, etc.). 
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ated with one of the following criteria: PaCO2 > 45 mmHg; 
episodes of desaturation during a night-time monitoring (SaO2 
<88% for 5 consecutive minutes); MIP < 60 cm H2O or a FVC 
< 50% of predicted values in patients with progressive neu-
romuscular diseases. According to the international consensus 
additional physiological criteria are: PaO2 in the waking state 
and during clinical stability < 60 mmHg, vital capacity (VC) 
< 20-30% predicted or < 1.0 L, maximum pressure inspiratory 
(MIP) < 30 cm H2O, unlike the CV in the transition from up-
right to supine position > 25%; tachypnoea: respiratory rate > 
27 breaths / min. Noninvasive mechanical ventilation helps pa-
tients to breathe when the muscle becomes deficient. It inter-
acts with the patient having an adequate alveolar ventilation, 
improving  oxygenation  and  reducing  hypercapnia.  Patients 
treated with noninvasive mechanical ventilation have reduced 
dyspnea and hypersomnia and improved sleep; also fatigue 
disappeared in most patients. 
In patients with Pompe disease progressive muscle weak-
ness renders ineffective the mechanism of cough, with stagnation 
of secretions. This causes atelectasias, pneumonia, acute respira-
tory failure with need for frequent hospitalization. airway clear-
ance techniques can facilitate the mobilization and removal of 
secretions that clutter the airways. The use of airway clearance 
techniques, including assisted coughing techniques, both manual 
and mechanical, and secretion mobilization techniques, is strong-
ly recommended. These techniques should always be included in 
the treatment of chronic NMD patients. Chest percussion and vi-
bration can help to mobilize peripheral airway secretions but they 
are not substitutes for coughing and, unlike for assisted coughing, 
have never been shown to decrease pulmonary morbidity and mor-
tality. Cough can be assisted by manual and mechanical means. 
There are a wide variety of techniques available from which to 
choose, ranging from manual techniques to mechanically assisted 
maneuvers. The possibility of using devices for assisted coughing 
should be individually evaluated. 
References
1.  Bembi B, Cerini E, Danesino C. Management and treatment of gly-
cogenosis type II. Neurology 2008;71:S12-36.
2.  Mellies U, Dohna-Schwake C, Voit T. Respiratory function assess-
ment and intervention in neuromuscular disorders. Curr Opin Neu-
rol 2005;18:543-7.
3.   Kishanni P, Steiner R, Bali D, et al. Pompe disease: diagnosis and 
management guideline. Genet Med 2006;8:267-88.
4.   Mellies U, Lofaso F. Pompe disease: a neuromuscular disease with 
respiratory muscle involvement. Resp Med 2009;103:477-84. 
S1.6 Dry blood spot: a new method for early 
diagnosis
M.A. Donati 
Not arrived